Takeda Pharmaceutical Company Limited (TAK)
| Previous close | 18.19 |
| Open | 18.40 |
| Bid | 18.19 x 800 |
| Ask | 18.20 x 1200 |
| Day's range | 18.18 - 18.39 |
| 52-week range | 12.43 - 20.93 |
| Volume | 257,947 |
| Avg. volume | 1,138,092 |
| Market cap | 57.185B |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | 22.45 |
| EPS (TTM) | 0.81 |
| Earnings date | N/A |
| Forward dividend & yield | 0.84 (4.61%) |
| Ex-dividend date | 30 Mar 2020 |
| 1y target est | 23.60 |
- Business Wire
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.
- Business Wire
BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana
BioLife Plasma Services announces opening of first plasma collection center in Louisiana.
- Motley Fool
Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study
The results provide more justification for the FDA to grant the substance emergency use authorization.
